USD10
AUPH Shares
About Aurinia PharmaceuticalsAurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
USD10
AUPH Shares
About Aurinia PharmaceuticalsAurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.99B
OPEN PRICE
$15.41
LOW (1Y)
$8.80
HIGH (1Y)
$19.25
LOW (24H)
$15.13
HIGH (24H)
$15.52
VOLUME (24H)
$792.97K
17.32%
Price history
Time | Price | Change |
|---|---|---|
Today | $15.41 | |
1 Day | $15.52 | |
1 Week | $16.05 | |
1 Month | $18.37 | |
1 Year | $8.89 |
Past performance is not a reliable indicator of future results.
Discover more
Popular prediction markets
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.
